|
Hanmi Science is a business-oriented holding company that generates revenue from equity interests, patent and trademark royalties, and direct healthcare operations. Its business segments include a holding division, a healthcare division, and a pharmaceutical wholesale division. The healthcare division comprises medical devices, consumer health products such as soy milk and functional foods, beauty care, and IT solutions for the pharmaceutical industry. The wholesale division operates the HMP Mall B2B e-commerce platform and a nationwide sales network to distribute pharmaceuticals, quasi-drugs, health functional foods, and automatic dispensing machines to pharmacies and hospitals. Key subsidiaries include Hanmi Pharm, which develops and manufactures drugs such as Amodactan, Rosujet, and Esomezol; J.V.M, which provides pharmacy and hospital automation systems; and Online Pharm, which handles pharmaceutical distribution. The group also includes Hanmi Precision Chemical for active pharmaceutical ingredients, Hanmi Europe Ltd. and Japan Hanmi Pharm for international expansion, and Evidnet for database and online information services. Hanmi Science serves domestic and international markets, with subsidiaries operating in Japan, Europe, and China. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - General | Homepage hanmiscience.co.kr |
| Sector Healthcare | IR page — | |
|
Tags
holding company, innovative drugs, complex generics, pharmaceutical distribution, pharmacy automation, medical devices, consumer health, functional foods, beauty care, pharmaceutical it, active pharmaceutical ingredients, Hanmi Pharm, J.V.M, Online Pharm, Hanmi Precision Chemical, Hanmi Europe Ltd., Japan Hanmi Pharm, Beijing Hanmi IT Co. Ltd., Evidnet, Amodactan, Rosujet, Esomezol, Palpal, Rovelito, HMP Mall, Hanmi Healthcare
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 3.014T |
| Market cap (USD) | $ 2.219B |
| P/E | 19.79 |
| PEG | 1.01 |
| P/BV | 2.84 |
| P/S | 2.14 |
| P/OCF | 64.29 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 13.1% |
| ROI | 12.3% |
| ROIC | 12.8% |
| Profit margin | 8.7% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 19.6% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 50.0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.357T | 1.283T | 1.248T | 1.046T | 950.165B | 857.383B | 816.619B | 707.995B | 652.324B | 665.285B | 776.629B | 532.886B | 220.396B |
| Net profit | 118.37B | 59.422B | 115.122B | 69.21B | 42.942B | 22.597B | 30.742B | 18.02B | 30.069B | 7.94B | 177.45B | 21.862B | 9.598B |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 127B | 108B | 101B | 91.1B | 87.9B | 94.2B | 99.8B | 109B | 103B | 105B |
| ↳ YoY growth | -47.0% | -15.5% | -5.7% | -10.2% | -3.5% | +7.2% | +5.9% | +8.8% | -5.3% | +2.5% |
| ↳ 5y CAGR | +9.2% | -6.2% | -18.2% | -5.8% | -1.5% | +1.4% | +2.5% | +3.7% | ||
| Borrowings, current (KRW) | 25B | 25B | 20B | 44B | 45B | 55B | 194B | 202B | 215B | 213B |
| Borrowings, non-current (KRW) | — | — | 0.00 | 0.00 | 5B | 0.00 | 5.82B | 10.2B | 350M | 0.00 |
| Cash and deposits (KRW) | 103B | 38.4B | 26.9B | 16.7B | 14.8B | 16.6B | 21.4B | 27.6B | 85.2B | 127B |
| Intangible assets (KRW) | 8.47B | 12.5B | 11.2B | 10.4B | 8.81B | 7.58B | 19.1B | 67.1B | 54.5B | 15.7B |
| Right-of-use assets (KRW) | — | 0.00 | 0.00 | 1.4B | 1.39B | 1.45B | 2.44B | 1.77B | 1.81B | 1.19B |
| Net debt (borrowings + leases - cash) (KRW) | -77.5B | -13.4B | -6.86B | 27.3B | 35.2B | 38.4B | 178B | 185B | 130B | 85.9B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | 76.5B | -33.7B | 2.7B | 13B | 13.8B | 13.7B | 9.45B | 35.2B | 83B | 47.7B |
| Change in receivables (cash effect) (KRW) | 116B | 19.5B | 33.7M | 9.43B | 3.6B | -5.41B | 3.74B | -8.78B | 5.44B | -3.12B |
| Change in inventories (cash effect) (KRW) | -3.58B | -14.3B | 5.55B | 2.73B | -8.52B | 2.73B | 6.24B | 9.71B | -4.05B | -13.9B |
| Change in payables (cash effect) (KRW) | 2.5B | -38.2B | -5.46B | -14.3M | -331M | -18.7B | -40.2B | -19.2B | 68.8B | -1.56B |
| Dividends paid (cash effect) (KRW) | -27.6B | 0.00 | -12.2B | -12.4B | -12.7B | -12.9B | -13.2B | -13.3B | -20.3B | -13.5B |
| Share buybacks (cash effect) (KRW) | -1.77B | -835M | -998M | -647M | -348M | -1.01B | -623M | -7.83B | -1.93B | 0.00 |
| Interest paid (cash effect) (KRW) | -975M | -751M | -624M | -1.22B | -1.13B | -1B | -2.6B | -9.53B | -9.28B | -7.73B |
| Income taxes paid (cash effect) (KRW) | -44.9B | -22.7B | -4.39B | -2.96B | -3.48B | -5.66B | -5.35B | -4.25B | -9.28B | -10.6B |
| Share-based compensation (KRW) | 13.5B | 1.27B | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 553M | 211M |
| Operating cash flow before change in receivables (KRW) | -39.1B | -53.2B | 2.67B | 3.59B | 10.2B | 19.1B | 5.71B | 43.9B | 77.5B | 50.8B |
| Income detail | ||||||||||
| Total comprehensive income (KRW) | 910M | 27.7B | 12.1B | 5.7B | — | 45.5B | 67.2B | 83.9B | 72.9B | 132B |
| Comprehensive income to owners (KRW) | 979M | 27B | 12.1B | 5.69B | — | 45.5B | 67.4B | 83.9B | 75.7B | 133B |
| Provision for credit losses (KRW) | 0.00 | 531M | 0.00 | 0.00 | 35.4M | 52.9M | 0.00 | 341M | 0.00 | 212M |
| Credit cost ratio (credit losses / average receivables) (%) | 0.0% | 0.5% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.3% | 0.0% | 0.2% |
| Reported | Apr 2, 2018 | Mar 30, 2020 | Mar 18, 2021 | Mar 18, 2021 | Mar 18, 2021 | Mar 28, 2024 | Mar 18, 2025 | Mar 18, 2025 | Mar 18, 2025 | Mar 20, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Hanmi Science
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.10% | 3,500 | $ 137.478K | Nov 16, 2026 |
| DFEV | 0.02% | 11,202 | $ 461.4K | Nov 12, 2026 |
| DFSE | 0.02% | 2,133 | $ 87.856K | Nov 12, 2026 |
| DEXC | 0.01% | 932 | $ 38.388K | Nov 12, 2026 |
| AVXC | 0.01% | 807 | $ 31.699K | Nov 16, 2026 |
| DFEM | 0.01% | 17,264 | $ 711.088K | Nov 12, 2026 |
| DFAE | 0.00% | 9,329 | $ 384.253K | Nov 12, 2026 |
| DFAX | 0.00% | 11,875 | $ 489.12K | Nov 12, 2026 |
| AVEM | 0.00% | 10,244 | $ 402.379K | Nov 16, 2026 |